Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the prostate except
neuroendocrine carcinoma including small cell carcinoma

- Disease progressed on or after prior docetaxel-containing chemotherapy

- Prior 1 or 2 cytotoxic chemotherapy regimens for metastatic castration-resistant
prostate cancer, at least 1 of which contains docetaxel

- Documented prostate cancer progression as documented by prostate specific antigen
progression according to Prostate Specific Antigen Working Group criteria or
radiographic progression in soft tissue or bone

- Surgically or medically castrated, with serum testosterone level <50 ng/dL (1.7
nmol/L)

- Eastern Cooperative Oncology Group performance status score of <=2

- Protocol-defined laboratory values

- Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

- Active infection or other medical condition that would make prednisone
(corticosteroid) use contraindicated

- Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg
prednisone twice daily

- Pathological finding consistent with neuroendocrine carcinoma of prostate including
small cell carcinoma

- Uncontrolled hypertension (systolic BP >=160 mmHg or diastolic BP >=95 mmHg; patients
with a history of hypertension are allowed provided blood pressure is controlled by
anti-hypertensive therapy)

- Active or symptomatic viral hepatitis or chronic liver disease, have a known
infection with human immunodeficiency virus and/or hepatitis B virus or hepatitis C
virus

- History of pituitary or adrenal dysfunction.

- Clinically significant heart disease as evidenced by myocardial infarction, or
arterial thrombotic events in the past 6 months, severe or unstable angina, or New
York Heart Association Class III or IV heart disease or cardiac ejection fraction
measurement of <50% at baseline

- Atrial fibrillation, or other cardiac arrhythmia requiring therapy

- Other malignancy within past 3 years (except basal or nonmetastatic squamous cell
carcinoma of the skin)

- Known brain metastasis

- Prior therapy with abiraterone acetate or other CYP17 inhibitor(s), or
investigational agent(s) targeting the androgen receptor for metastatic prostate
cancer

- Prior therapy with ketoconazole for prostate cancer

- Surgery or local prostatic intervention within 30 days of the first dose

- Radiotherapy, chemotherapy, or immunotherapy within 30 days, or single fraction of
palliative radiotherapy within 14 days of administration of Cycle 1 Day 1

- Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not
resolved to a National Cancer Institute-Common Terminology Criteria for Adverse
Events grade of <=1 (chemotherapy induced alopecia and grade 2 peripheral neuropathy
is allowed)

- Current enrollment in an investigational drug or device study or participation in
such a study within 30 days of Cycle 1 Day 1

- Anti-androgen treatment must not be given within 4 weeks (flutamide) or 6 weeks
(bicalutamide or nilutamide) prior to Cycle 1 Day 1

- Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole) within 4
weeks prior to Cycle 1 Day 1

- Has known allergies, hypersensitivity, or intolerance to abiraterone acetate or its
excipients

- Has contraindications to the use of prednisone per local prescribing information

- Has any condition that, in the opinion of the investigator, would make participation
not be in the best interest (eg, compromise the well-being) of the patient or that
could prevent, limit, or confound the protocol-specified assessments